Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Patient Ambassador Support in Newly Diagnosed Patients With Acute Leukemia During Treatment (PAS)

9 marzo 2021 aggiornato da: Kristina Holmegaard Nørskov, Rigshospitalet, Denmark

Patient Ambassador Support in Newly Diagnosed Patients With Acute Leukemia During Treatment: a Feasibility Study

Background: Acute leukemia is a life threatening hematological malignancy which can result in substantial symptom burden including impaired psychological wellbeing. Peer-to-peer support has positive and beneficial effects on patients with cancer. Yet there is lack of knowledge and evidence of the feasibility and the effect of peer-to-peer support on patient with acute leukemia

Aims: The study aim to examine the feasibility and safety of Patient Ambassador Support in newly diagnosed patients with acute leukemia during treatment, and to examine the benefit on symptoms and psychological wellbeing in both patients and ambassadors.

Design and methods: This study is a one arm feasibility intervention trial with patients n=40; patient ambassadors (PA) n=30. Patients will be consecutively recruited at the Departments of Hematology, Rigshospitalet, Herlev and Gentofte Hospital and Sjællands Universitetshospital, Roskilde, and paired with a PA who will follow and assist the patient over the course of two series of chemotherapy for a 12 week period, with one follow-up contact at 3 month. Data is collected at baseline (within 2 weeks of diagnosis), post intervention (12 weeks) and follow-up 6 months.

Implication: This study has the potential to be a new model for care incorporated in the oncology/hematology clinical care setting, creating an active partnership between patients and former patients; and in collaboration with the health care professionals which may strengthen the existing care and support system.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Study Part 2 Aim To investigate the feasibility and safety of Patient Ambassador Support (PAS) and whether there is benefit on psychological wellbeing and symptoms among newly diagnosed patients with acute leukemia and among former patients with acute leukemia (patient ambassadors).

Design and Methods A one arm feasibility intervention trial with patients (n=40) and patient ambassadors (PA) (n=30).

Recruitment Patients will be recruited at three Danish hematology departments: Rigshospitalet (RH), Herlev og Gentofte Hospital (HGH and Sjællands Universitetshospital, Roskilde (SUR), from January 2018 to June 2019. Eligible patients receive oral and written project information from KHN within two weeks from diagnosis. KHN provides a summary of the study and gives the opportunity to raise questions or concerns related to the study.

PA´s will be recruited voluntarily from the patient association LyLe and from the outpatient hematology departments of RH, HGH and SUR by KHN, and screened by interview to assess their appropriateness for the intervention. Screening interviews include questions about a survivor´s motivation for volunteering, availability, ability to respect confidentiality, and ability to acknowledge the vulnerability that may occur when they revisiting experience of others with acute leukemia. The PA is obligated to sign a confidentiality commitment, and knows and accepts the terms and requirements included in the intervention. Furthermore, the PA provides information regarding age, gender, diagnose, treatment, interests, work, education, social conditions in order to match with patients. The PA must provide transportation themselves but will receive a monetary incentive for their participation. During the intervention we will adjust the PA recruitment process in order to fill specific needs in the program such as age groups or diagnosis. This will ensure that we do not have a larger ambassador pool than we effectively utilize.

Patients and ambassadors who have consented and agreed to participate in the study will complete the baseline testing (patient reported outcome questionnaires) before the beginning of intervention.

Patient ambassador training program Recruited PAs will receive a group training program, curriculum and an ambassador 'checklist´. Before interacting with patients, the PA will receive 6 hours of training. The training will be organized by KHN and a project nurse from each intervention site. The training will be carried out by KHN, the project nurse, a represent from the PAB and a psychologist. Training modules include information on medical facts related to acute leukemia, information on psychosocial issues, training in communication skills with emphasis on active listening, and learning how to help other patients problem- solve and advocate for themselves within the health care system. Training also includes discussion of the PA ´s personal goals and concerns about volunteering in the study and their individual attitudes toward survivorship and illness. The importance of maintaining appropriate boundaries are discussed, to ensure PA do not overly identify with patients and remain aware of their role as listening mentors who use their experience only when solicited by the patient. Further, possible changes in medical conditions in both themselves and the patients will be discussed. The PA is offered supervision during the intervention and the opportunity to attend ambassador support meetings every second month for ongoing education and to process their experiences with patients.

Match between patients and ambassadors Patients and ambassadors express prior to intervention which preferences they have for their match. They will be matched according to diagnosis, age, gender and other factors that might create a mutual understanding and ease of communication. KHN will pair patients with a PA. If it is not possible to match on the given preferences, the patient and ambassador will be involved in the decision.

PAS intervention The intervention consists of support provided by the PA, who will follow and assist the patient over the course of 12 weeks, through two series of chemotherapy. The intervention consists of minimum four face-to-face meetings between patient and PA and additionally open telephone and/or email contact based on the patients 'individual needs, including one follow-up contact at 3 months by telephone. The duration of the contact is individual. The context of the face-to-face meetings are chosen between patients and ambassadors e.g. café on the local hospital, a café near both patient and ambassador or private based on the contact developed between patient and ambassador. The PA will follow one patient at a time, however at the end of the 12 week period; the PA can choose to follow a new patient. During the first meeting, an expectation agreement between the patient and PA will be discussed and signed. The PA will use an ambassador checklist to document the frequency, content and quality of the connections between patient and PA, as well as documenting themes, goals, progress and outcomes of their conversations. The checklist will be developed in conjunction with representatives from the PAB and prior to the recruitment of the IG. The checklist will provide a comprehensive guidance and list of important and relevant actions, or steps to be taken in the role as PA, as well as serve as a work and documentation tool during the intervention and follow-period. Upon completion of the training program each PA will receive a training certificate and a personal PA name badge.

Changes in medical conditions in both patients and ambassadors which will affect their ability to participate in the study will result in exclusion. The project nurse at the specific hematologic department reports to the primary investigator (KHN) within 48 hours. Changes in medical conditions comprise the following conditions: relapse (ambassadors), critical psychological conditions including delirium or severe depression, hospitalization in intensive care unit (ICU) longer than two weeks or transition to palliative care.

Safety net - ambassadors' support There will be held an ambassador support meeting which is important to allow the ambassadors to share experiences, solve problems, and provide mutual support. The ambassadors have the possibility to request supervision from a psychologist during the intervention. The psychological health of the ambassadors is of great interest and it is important that they do not suffer unnecessary distress following the intervention. Any adverse events will be documented and acted on.

Outcomes measurements and data collection Data are collected by patient reported outcome measures (PROM) completed by patients electronically prior to intervention, post intervention (12 weeks) and at 3-month follow-up. PROM is completed by PA, after they have completed the patient ambassador training program, but prior to their first PAS intervention and at post intervention (12 weeks). Socio-demographic characteristics are collected through by patient's medical charts and questionnaire.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

61

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Herlev, Danimarca, 2730
        • Herlev Hospital
      • Roskilde, Danimarca, 4000
        • Sjællandsuniversitetshospital Roskilde
    • Østerbro
      • Copenhagen, Østerbro, Danimarca, 2100
        • Rigshospitalet

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Eligible patients are > 18 years and newly diagnosed with acute leukemia < 2 weeks of diagnosis who are planned to receive intensive treatment during a course of minimum two series of chemotherapy, and ambassadors (PA) > 18 years who have completed treatment for their acute leukemia > 6 month (in complete remission) and provides consent to participate in the ambassador training program, and applicable to all participants (patients and PA) written informed consent is provided.

Exclusion Criteria:

  • Patients and ambassadors are excluded if they do not understand, read and speak Danish, if they have unstable medical disease or cognitive / psychiatric disorders.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Intervention
Patient Ambassador Support
Patient Ambassador Support, with former patient treated for acute leukaemia being ambassadors for newly diagnosed patients for a period of 12 weeks.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Tasso di reclutamento
Lasso di tempo: Fino a 2 anni
Numero di partecipanti inclusi da pazienti idonei
Fino a 2 anni
Adherence to intervention
Lasso di tempo: Up to 24 weeks
number of weeks completed out of planned weeks of intervention
Up to 24 weeks
Emotional reactions (Total numbers of contacts with project team members)
Lasso di tempo: Up to 24 weeks
Measured by registration on numbers of contact made by participants to primary investigator / project psychologist / project nurse
Up to 24 weeks
Emotional reactions (content of contacts with project team members)
Lasso di tempo: Up to 24 weeks
Measured by registration quality of contact made by participants to primary investigator / project psychologist / project nurse
Up to 24 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Quality Of Life
Lasso di tempo: Change measures (baseline, 12 weeks, and 24 weeks)
Measured with the EORTC Quality of Life Questionnaire (EORTC QLQ-C30)
Change measures (baseline, 12 weeks, and 24 weeks)
Symptom burden
Lasso di tempo: Change measures (baseline, 12 weeks, and 24 weeks)
Measured with the M.D. Anderson Symptom Inventory (MDSAI) patient questionnaire
Change measures (baseline, 12 weeks, and 24 weeks)
Patient Activation Measure
Lasso di tempo: Change measures (baseline, 12 weeks, and 24 weeks)
Measured with the Patient activation measure (PAM) questionnaire
Change measures (baseline, 12 weeks, and 24 weeks)
Anxiety and Depression
Lasso di tempo: Change measures (baseline, 12 weeks, and 24 weeks)
Measured with the The Hospital Anxiety and Depression Scale (HADS) patient questionnaire
Change measures (baseline, 12 weeks, and 24 weeks)
Quality of Life
Lasso di tempo: Change measures (baseline, 12 weeks, and 24 weeks)
Measured with the Functional Assessment of Cancer Therapy - Leukemia (FACT-LEU)
Change measures (baseline, 12 weeks, and 24 weeks)
Self-efficacy
Lasso di tempo: Change measures (baseline, 12 weeks, and 24 weeks)
Measured with the The General Self-Efficacy Scale patient questionnaire
Change measures (baseline, 12 weeks, and 24 weeks)
Hospital admissions (total number of admissions)
Lasso di tempo: Up to 24 weeks
Data will be collected from medical charts
Up to 24 weeks
Hospital admissions (causes)
Lasso di tempo: Up to 24 weeks
Data will be collected from medical charts
Up to 24 weeks
Hospital admissions (days)
Lasso di tempo: Up to 24 weeks
Data will be collected from medical charts
Up to 24 weeks
Proportion of participants with overall survival up to 24 weeks
Lasso di tempo: Up to 24 weeks
Data will be collected from medical charts
Up to 24 weeks
Infezioni (tipo)
Lasso di tempo: Fino a 24 settimane
I dati saranno raccolti dalle cartelle cliniche
Fino a 24 settimane
Infezioni (giorni)
Lasso di tempo: Fino a 24 settimane
I dati saranno raccolti dalle cartelle cliniche
Fino a 24 settimane
Physical activity level
Lasso di tempo: Change measures (baseline, 12 weeks, and 24 weeks)
Leisure Time Physical Activity Scale
Change measures (baseline, 12 weeks, and 24 weeks)
Number of contacts between patient and ambassador
Lasso di tempo: Up to 12 weeks
Measured by the total number of contacts during 12 week of intervention
Up to 12 weeks
Length of contacts between patient and ambassador
Lasso di tempo: Up to 12 weeks
Measured by the total time of contacts during 12 week of intervention
Up to 12 weeks
Thematic content of the contacts between patient and ambassador
Lasso di tempo: Up to 12 weeks
Measured by ambassadors thematic registration of the contacts with the patient
Up to 12 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Mary E Jarden, ph.d., Rigshospitalet, Denmark

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 marzo 2018

Completamento primario (Effettivo)

1 settembre 2019

Completamento dello studio (Effettivo)

1 settembre 2019

Date di iscrizione allo studio

Primo inviato

5 gennaio 2018

Primo inviato che soddisfa i criteri di controllo qualità

3 aprile 2018

Primo Inserito (Effettivo)

11 aprile 2018

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 marzo 2021

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 marzo 2021

Ultimo verificato

1 marzo 2021

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • Rigshospitalet PAS

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

Indeciso

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi